

# Our Global Statement on Product Stewardship

BeiGene's mission is to build a next-generation global oncology company—one that expands the highest-quality therapies to people around the world—through courage, persistent innovation, and challenging the status quo.

A byproduct of patients benefiting from life-saving medical treatments worldwide is a small but notable amount of pharmaceutical products detected in sewage water, ground water, and potable water, posing risks to humans and wildlife. Pharmaceuticals typically enter the environment via human excretion, the manufacturing of pharmaceutical products, or improper disposal of unused medicines.<sup>1</sup> While the potential for virulent effects from pharmaceuticals in the environment on human health remain low, we continue to mitigate this risk whenever possible.

## BeiGene's Position

As a company focused on improving health and increasing health equity, minimizing our impact on the earth's life-sustaining systems is a key aspect of our sustainability commitment. To this end, BeiGene has developed a global climate strategy that seeks to understand and minimize our environmental impacts, especially within our research and manufacturing facilities. Further, we strive to mitigate the impact of our products throughout manufacturing, distribution, and end of life use. As a signatory of the United Nations Global Compact, we align our initiatives with the UN's Sustainable Development Goals with a particular focus on Climate Action,

## BeiGene's Approach

To better address the challenges related to pharmaceuticals in the environment, BeiGene uses a multi-prong approach that touches all stages of the product life cycle.

### Environmental Risk Assessment

BeiGene conducts environmental risk assessments (ERAs) on our products from initial development to market release to identify and manage any potential impacts arising from production and consumer usage. These assessments are performed in compliance with strict international standards, including those set by the U.S. Food and Drug Administration and the European Medicines Agency during their regulatory reviews. We regularly update our product ERAs at the time of filing product renewals and take necessary risk mitigation measures as required.

### Manufacturing

BeiGene assesses new chemicals introduced into our owned and operated manufacturing

---

<sup>1</sup> <https://www.efpia.eu/about-medicines/development-of-medicines/regulations-safety-supply/pharmaceuticals-in-the-environment-pie/>

facilities for potential environmental impacts. We have developed a comprehensive Environmental Health and Safety system across all BeiGene facilities, and our manufacturing processes are in compliance with ISO 14001 and 45001 standards. Our owned and operated facilities in China completed environmental impact assessments (EIA) prior to construction. Each EIA is reviewed and approved by local regulatory authorities.

BeiGene follows established procedures to minimize the discharge of active pharmaceutical ingredients, and we work with our suppliers to ensure they are aware of our environmental standards and commitments.

We aim to reuse water whenever possible by recycling cleaner quality water for less sensitive purposes such as landscaping and cooling water tower replenishment. Wastewater is treated at on-site wastewater treatment facilities or at external treatment plants in accordance with local requirements. We maintain compliance with local regulations and permitting for wastewater discharge and engage a qualified third party to regularly monitor the quality of our effluent to ensure compliance with local discharge standards.

We strive to reduce hazardous waste whenever possible. Hazardous waste produced in manufacturing and laboratories is collected and stored in compliance with applicable laws and regulations and transported to qualified third-party vendors for disposal. Non-hazardous waste, which includes domestic waste produced in office operations and non-hazardous waste from production, is recycled, reduced/reused whenever possible and incinerated or disposed by an approved third party or municipal sanitary station as a last resort.

### **Unused Medicines and Takeback Programs**

BeiGene is committed to proper disposal of our products. Any returned or flagged products are properly managed and incinerated by a licensed and approved third party. BeiGene is a member of the Pharmaceutical Product Stewardship Working Group, which coordinates industry efforts including providing access to drug takeback programs for consumers. To dispose of unwanted household medications in the United States, visit [www.myoldmeds.com](http://www.myoldmeds.com) to find the nearest disposal location.

### **Stakeholder Engagement**

We work with suppliers that share our commitment to high quality products and responsible operation. We outline our expectations in our global Supplier Code of Conduct which suppliers are required to adhere to at the onset of their contract with us. If we are aware of any behaviors or conditions not in compliance with our standards, we take immediate action to communicate these issues, work with our suppliers to develop a mitigation plan and take remedial action steps to return to compliance. The Supplier Code of Conduct is reviewed internally each year.